Skip to main content

Remote Job Finders (RJF)

Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.

All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts

Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.
Scroll to top